D. Lynn Kirkpatrick

2.3k total citations
34 papers, 1.8k citations indexed

About

D. Lynn Kirkpatrick is a scholar working on Molecular Biology, Biochemistry and Cancer Research. According to data from OpenAlex, D. Lynn Kirkpatrick has authored 34 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 8 papers in Biochemistry and 6 papers in Cancer Research. Recurrent topics in D. Lynn Kirkpatrick's work include Redox biology and oxidative stress (10 papers), Sulfur Compounds in Biology (7 papers) and Glutathione Transferases and Polymorphisms (6 papers). D. Lynn Kirkpatrick is often cited by papers focused on Redox biology and oxidative stress (10 papers), Sulfur Compounds in Biology (7 papers) and Glutathione Transferases and Polymorphisms (6 papers). D. Lynn Kirkpatrick collaborates with scholars based in United States and Canada. D. Lynn Kirkpatrick's co-authors include Garth Powis, Sarah J. Welsh, Ryan Williams, Amanda F. Baker, Nathan T. Ihle, M. Martín Angulo, Peter Wipf, Anne Birmingham, David Newman and Mei Yee Koh and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

D. Lynn Kirkpatrick

33 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Lynn Kirkpatrick United States 18 1.4k 436 282 224 189 34 1.8k
Evan R. Lewis United States 13 1.3k 1.0× 701 1.6× 467 1.7× 86 0.4× 131 0.7× 20 2.0k
William P. Katt United States 22 946 0.7× 602 1.4× 315 1.1× 213 1.0× 147 0.8× 38 1.5k
Wei-Qun Ding United States 24 1.5k 1.1× 989 2.3× 379 1.3× 111 0.5× 152 0.8× 38 2.2k
Ana M. Tari United States 31 1.7k 1.3× 367 0.8× 708 2.5× 161 0.7× 167 0.9× 65 2.6k
Lorenzo Citti Italy 25 1.7k 1.3× 932 2.1× 330 1.2× 111 0.5× 96 0.5× 98 2.5k
Johannes Roesel Switzerland 23 1.5k 1.1× 750 1.7× 419 1.5× 255 1.1× 372 2.0× 36 2.8k
Zhao Chen China 23 1.9k 1.4× 731 1.7× 609 2.2× 88 0.4× 144 0.8× 72 2.5k
Dae‐Ghon Kim South Korea 28 1.3k 0.9× 577 1.3× 365 1.3× 75 0.3× 142 0.8× 49 2.1k
Jacinta Serpa Portugal 26 1.1k 0.8× 501 1.1× 319 1.1× 62 0.3× 257 1.4× 77 2.0k
Kristin Brown United States 19 924 0.7× 244 0.6× 300 1.1× 132 0.6× 87 0.5× 33 1.4k

Countries citing papers authored by D. Lynn Kirkpatrick

Since Specialization
Citations

This map shows the geographic impact of D. Lynn Kirkpatrick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Lynn Kirkpatrick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Lynn Kirkpatrick more than expected).

Fields of papers citing papers by D. Lynn Kirkpatrick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Lynn Kirkpatrick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Lynn Kirkpatrick. The network helps show where D. Lynn Kirkpatrick may publish in the future.

Co-authorship network of co-authors of D. Lynn Kirkpatrick

This figure shows the co-authorship network connecting the top 25 collaborators of D. Lynn Kirkpatrick. A scholar is included among the top collaborators of D. Lynn Kirkpatrick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Lynn Kirkpatrick. D. Lynn Kirkpatrick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kirkpatrick, D. Lynn, et al.. (2024). Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers. Clinical and Translational Science. 17(3). e13765–e13765. 1 indexed citations
2.
Kirkpatrick, D. Lynn, et al.. (2017). In vitro and in vivo assessment of the abuse potential of PF614, a novel BIO-MD™ prodrug of oxycodone. Journal of Opioid Management. 13(1). 39–49. 5 indexed citations
3.
Kirkpatrick, D. Lynn & Garth Powis. (2016). Clinically Evaluated Cancer Drugs Inhibiting Redox Signaling. Antioxidants and Redox Signaling. 26(6). 262–273. 38 indexed citations
4.
Scott, Mike, et al.. (2014). Abstract 2671: Targeting the KRAS signaling naocluster protein CNKSR1 provides antitumor activity against mutant KRAS xenografts. Cancer Research. 74(19_Supplement). 2671–2671. 1 indexed citations
5.
Koh, Mei Yee, Taly R. Spivak-Kroizman, Sara Venturini, et al.. (2008). Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1α. Molecular Cancer Therapeutics. 7(1). 90–100. 242 indexed citations
6.
Powis, Garth & D. Lynn Kirkpatrick. (2007). Thioredoxin signaling as a target for cancer therapy. Current Opinion in Pharmacology. 7(4). 392–397. 220 indexed citations
7.
Baker, Amanda F., Tomislav Dragovich, Wendy R. Tate, et al.. (2006). The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. Journal of Laboratory and Clinical Medicine. 147(2). 83–90. 77 indexed citations
8.
Powis, Garth, Nathan T. Ihle, & D. Lynn Kirkpatrick. (2006). Practicalities of Drugging the Phosphatidylinositol-3-Kinase/Akt Cell Survival Signaling Pathway. Clinical Cancer Research. 12(10). 2964–2966. 33 indexed citations
9.
Hashash, Ahmad, D. Lynn Kirkpatrick, Merrill J. Egorin, Lawrence H. Block, & John S. Lazo. (2002). Normal-phase and stability-indicating reversed-phase high-performance liquid chromatographic methods for the determination of the novel antitumor agent: 1-methylpropyl-2-imidazolyldisulfide. Journal of Chromatography B. 768(2). 239–246. 4 indexed citations
10.
Powis, Garth, D. Lynn Kirkpatrick, M. Martín Angulo, & Amanda F. Baker. (1998). Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chemico-Biological Interactions. 111-112. 23–34. 87 indexed citations
11.
Kirkpatrick, D. Lynn, Noëlle Potier, Lynda J. Donald, et al.. (1998). Mechanisms of Inhibition of the Thioredoxin Growth Factor System by Antitumor 2-Imidazolyl Disulfides. Biochemical Pharmacology. 55(7). 987–994. 118 indexed citations
12.
Kirkpatrick, D. Lynn, et al.. (1996). Oxidative inactivation of thioredoxin as a cellular growth factor and protection by a Cys73 → Ser mutation. Biochemical Pharmacology. 52(11). 1741–1747. 59 indexed citations
13.
Kirkpatrick, D. Lynn, et al.. (1994). Synthesis and bioreductive potential of a mono Noxide derivative of the alkylating agent chlorambucil. Anti-Cancer Drugs. 5(4). 467–472. 4 indexed citations
14.
Kirkpatrick, D. Lynn, et al.. (1994). High-performance liquid chromatographic method for the separation of chlorambucil and its N-oxide prodrug. Journal of Chromatography B Biomedical Sciences and Applications. 652(2). 195–202. 4 indexed citations
15.
Oblong, John E., et al.. (1994). Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues. Cancer Chemotherapy and Pharmacology. 34(5). 434–438. 2 indexed citations
16.
Kirkpatrick, D. Lynn, et al.. (1992). Modification of the DiSC assay by the incorporation of monoclonal antibody staining. Leukemia Research. 16(11). 1097–1103. 2 indexed citations
17.
Kirkpatrick, D. Lynn, et al.. (1992). Effect of a hypoxic tumor cell cytotoxic disulfide on the membrane and DNA of tumor cells in culture. Anti-Cancer Drugs. 3(6). 651–658. 1 indexed citations
18.
Kirkpatrick, D. Lynn, et al.. (1990). Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay. Leukemia Research. 14(5). 459–466. 37 indexed citations
19.
Kirkpatrick, D. Lynn, et al.. (1990). Inhibitory effects of cytotoxic disulfides on membrane Na+,K+-ATPase. Biochemical Pharmacology. 39(9). 1484–1487. 2 indexed citations
20.
Kirkpatrick, D. Lynn. (1989). Kinetic study of the interaction of glutathione with four antitumor disulfides: Possible mechanism for cellular glutathione depletion. Chemico-Biological Interactions. 69(2-3). 225–234. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Evan R. Lewis Breakdown of academic impact, for papers by William P. Katt Breakdown of academic impact, for papers by Wei-Qun Ding Breakdown of academic impact, for papers by Ana M. Tari Breakdown of academic impact, for papers by Lorenzo Citti Breakdown of academic impact, for papers by Johannes Roesel Breakdown of academic impact, for papers by Zhao Chen Breakdown of academic impact, for papers by Dae‐Ghon Kim Breakdown of academic impact, for papers by Jacinta Serpa Breakdown of academic impact, for papers by Kristin Brown
Rankless by CCL
2026